Evotec stock gains on Plectonic deal as TecDAX name rebounds

Published on 09/03/2026 at 15:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock is recovering from recent lows after a new research alliance on T-cell approaches for solid tumors, with the TecDAX-listed drug discovery group also showing fresh price momentum on Xetra.

Geometrisches Bauhaus-Poster in Rot Gelb Blau mit großem Schriftzug PHARMA — Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA steht sinnbildlich für Evotec SE, ISIN DE0005664809, Biotech-Branche, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) stock was quoted at around 3.32 EUR on Xetra as of September 3, 2026, showing a modest intraday gain of 0.5 percent after a sharper move the previous day linked to a new oncology collaboration. Market data from finanzen.ch indicate that the Hamburg-based drug discovery specialist is still trading close to its recent lows, but the latest news around T-cell approaches for solid tumors has given the share price some support.

Research alliance drives price reaction

The key short-term catalyst is a new research collaboration between Evotec and Plectonic Biotech focusing on next-generation T-cell-engaging approaches against solid tumors, which was highlighted on September 2, 2026. An article on IT-Boltwise reports that Evotec shares rose by around 1.5 percent on September 2, 2026, to 3.20 EUR during the midday Xetra session, after opening at approximately 3.13 EUR. That move followed a wider intraday range between 3.13 EUR and 3.20 EUR, suggesting a cautious but positive market response.

A separate price overview compiles the reaction in the American depositary shares: Evotec SE American Depositary Shares, listed under the symbol EVO in the United States, posted a gain of 5.56 percent against the September 1, 2026 close, with the move explicitly classified as being driven by a contract or partnership announcement about the Plectonic collaboration. A rankings overview on StockTitan lists a market capitalization of about 675.2 million USD for Evotec SE American Depositary Shares as of early September 2026, underlining that even relatively small percentage moves translate into significant value swings for investors.

Short-term performance and TecDAX context

In the German market, Evotec is a member of the TecDAX index, and recent volatility has been pronounced. A report by wallstreet-online notes that on September 2, 2026, Evotec shares on Xetra climbed by about 3.75 percent during the trading day, reaching a level of approximately 3.2910 EUR by late evening. This followed a decline of roughly 2.07 percent the previous day, meaning that within just two sessions the stock swung from a clear loss to a corresponding gain, a pattern that illustrates the sensitivity of the price to pipeline and partnership headlines.

Intraday snapshots from September 3, 2026 confirm that the stock is attempting to stabilize slightly higher: Evotec shares were up about 1.3 percent at 3.35 EUR in the morning Xetra trading around 9:28, and later hovered around 3.32 EUR at mid-day, indicating a narrow band of positive movement rather than a strong breakout. Finanzen.ch intraday data frame this as a continuation of the short-term recovery from the previous session’s jump rather than a fresh trend change.

Go deeper

More on Evotec stock and fundamentals

For additional regulatory filings, detailed quarterly figures and further news on Evotec stock, the following resources provide a starting point.

Latest coverage on this ISIN Investor Relations

Drug discovery platform and oncology focus

Evotec operates a broad-based drug discovery and development platform, working both on its own pipeline and in alliances with major pharmaceutical and biotechnology companies. The collaboration with Plectonic Biotech fits this model: according to coverage of the agreement dated September 2, 2026, the partners aim to explore new generations of T-cell-engaging therapeutics that could address solid tumors, an area where existing immuno-oncology approaches still face significant challenges. The IT-Boltwise article emphasizes that, despite the share price move being only in the low single-digit percent range, the scientific scope of the deal could become more important over time as data emerge.

From an investor’s perspective, such alliances are central to Evotec’s value proposition: they typically bring in research funding and potential milestone payments while spreading development risk. At the same time, the modest reaction of about 1.5 percent on September 2, 2026 in the German listing and about 5.56 percent in the American depositary shares underscores that the market is currently cautious, reacting positively but not extrapolating the deal into a broader rerating. The StockTitan overview categorizes the move specifically under contract and partnership news, which suggests that traders see it primarily as an incremental pipeline enhancement rather than a transformational shift.

Stock price and investor takeaway

As of September 3, 2026, Evotec stock continues to trade on Xetra with an intraday level around 3.32 EUR and a small gain of 0.5 percent in mid-day trading, while earlier in the morning the shares were up around 1.3 percent at 3.35 EUR. The finanzen.ch midday snapshot and the corresponding morning quote jointly illustrate a narrow trading corridor around the lower single-digit euro level, with short-term performance driven mainly by the news flow from research alliances such as the Plectonic deal.